Innovation-Pushed Transformation Progresses with Portfolio Optimization and Broader Market Entry
HONG KONG SAR – EQS Newswire – 26 August 2026 – A completely built-in biopharmaceutical firm – Uni-Bio Science Group Restricted (“Uni-Bio Science”, along with its subsidiaries known as the “Group”, inventory code: 0690.HK), is happy to announce its interim outcomes for the six months ended 30 June 2026 (the “Interval”).
Key Accomplishments within the First Half of 2026
Throughout the Interval, the Group achieved a spectrum of accomplishments, for each of its marketed merchandise and revolutionary biologics. The important thing highlights embrace:
1. Throughout the Interval, the Group’s income reached roughly HK$273.8 million, with web revenue standing at roughly HK$31.2 million. Money era remained strong, with working money movement at roughly HK$11.4 million. Regardless of non permanent earnings compression ensuing from regulatory changes and front-loaded investments in R&D, commercialization, and worldwide enlargement, the Group demonstrated operational resilience by remaining worthwhile and financially robust.
2. As at 30 June 2026, complete fairness elevated by 8.6% to roughly HK$448.7 million, reflecting a strengthened capital base. The debt-to-equity ratio improved to 34.9%, demonstrating lively deleveraging and prudent capital stewardship. The Group stays in a web money optimistic place, with a money ratio nicely above 1, indicating that money and money equivalents considerably exceed near-term liabilities. This robust liquidity cushion allows the Group to comfortably take in the non permanent discount in web revenue through the Interval with out compromising its monetary stability. Collectively, these strengths place the Group to help future R&D funding, commercialization initiatives, and worldwide enlargement.
3. Income of Bogutai® elevated considerably by 39.3% year-on-year (“YoY”), pushed by the continued market growth and engagement with this revolutionary osteoporosis remedy inside the medical neighborhood and amongst sufferers in China. As of the primary quarter of 2026, Bogutai® ranked second in total market share and first within the retail channel amongst teriparatide merchandise in China. Its nationwide gross sales surpassing these of the originator model, reaching these market positions inside roughly two years of economic launch.
4. Throughout the Interval, the Group formally commenced the industrial launch and market promotion of its high-end collection, GeneQueens®, additional enriching its portfolio in practical skincare and post-procedure medical aesthetics. The premium line incorporates a proprietary triple-protein advanced (Fibronectin, Sort III Collagen, and Sort XVII Collagen), every formatted at a excessive focus of 1,000 ppm to optimize mobile restore and anti-aging efficiency. This milestone demonstrates concrete progress in accelerating the commercialization of its artificial biology platform.
5. The Group is advancing the event of its BMP-2 regenerative drugs program. Using its proprietary ECO-KSFA® platform, the Group has efficiently established a high-yield manufacturing course of for BMP-2 API, an important progress think about regenerative drugs broadly utilized in spinal fusion and bone defect reconstruction. Throughout the Interval, the Group accomplished pilot-scale manufacturing course of for the BMP-2 drug substance and initiated growth of a sustained-release gel formulation, laying a strong basis for finalizing the product’s medical dosage kind.
6. The following-generation generic antifungal drug, Isavuconazonium sulfate capsules, accomplished all supplementary research required by the regulator and the Group is getting ready to submit the corresponding documentation to the Heart for Drug Analysis (CDE) within the second half of 2026. To help future commercialization, the Group has commissioned a devoted manufacturing line particularly designed for the product and established strategic partnerships with high-quality API suppliers to make sure dependable manufacturing capability and provide for commercialization.
Interim Outcomes
The primary half of 2026 marked a strategic transition interval for the Group, characterised by portfolio optimization alongside increasing channel and market entry. Income through the Interval was quickly impacted by strategic volume-based procurement (VBP) pricing changes for Pinup® and, to a lesser extent, GeneTime®, coupled with the structural impression of newest biologics value-added tax (VAT) insurance policies on web promoting worth. For the Interval, the Group recorded income of roughly HK$273.8 million, representing a lower of 11.7% YoY.
Income of Bogutai® elevated considerably from roughly HK$65.6 million to roughly HK$91.4 million, representing a rise of 39.3%. Income of Boshutai® elevated by 50.8% from roughly HK$6.1 million to roughly HK$9.2 million. GeneTime® recorded a lower of 12.3% in income from roughly HK$107.8 million to roughly HK$94.5 million. Gross sales quantity of GeneTime® achieved high-single-digit YoY progress, reflecting continued robust underlying demand and the preliminary advantages of broader hospital entry and prescription-base enlargement. GeneSoft® recorded a 1.6% YoY enhance in income from roughly HK$18.5 million to roughly HK$18.8 million. Pinup® recorded a lower of 47.1% in income from roughly HK$108.9 million to roughly HK$57.6 million. With a restricted variety of product portfolio and the continued optimization of its advertising and distribution groups, income from 肌顏態® elevated from roughly HK$1.3 million to roughly HK$2.2 million, representing a 69.2% YoY progress. Income contribution from the Group’s newly launched medical gadget product 金因敷® and 金因康® (Diquafosol Sodium Eye Drops) had been immaterial through the Interval. The Group is increasing its digital and social media presence to lift 金因敷® model consciousness, whereas advancing focused private channel enlargement to speed up 金因康® uptake.
Gross revenue was roughly HK$222.7 million, representing a lower of 12.4% as in contrast with roughly HK$254.1 million for the primary half of 2025, whereas as gross revenue margin remained secure at 81.3%. Revenue for the Interval decreased by 59.0% YoY to roughly HK$31.2 million. The lower primarily mirrored short-term profitability stress through the Group’s strategic transformation, together with decrease absolute gross revenue ensuing from pricing changes for sure core merchandise and the VAT-related pricing impression, along with continued funding in commercialization, new product launches, pipeline growth, and worldwide enlargement. The earnings per share had been roughly HK$0.52 cents, in contrast with HK$1.27 cents within the first half of 2025.
Prospects
By means of focused industrial and R&D investments within the first half of 2026, the Group enters the second half nicely positioned to speed up its enterprise transformation. As generic therapies proceed to yield floor to higher-margin biopharmaceuticals inside the Group’s portfolio, this evolving income combine is anticipated to ship sustained margin enlargement over the long run. With biopharmaceuticals acknowledged for the primary time as an rising pillar trade supported by the state, the Group is dedicated to rising its innovation capabilities and increasing its industrial attain to seize this rising market alternative.
Mr. Kingsley Leung, Chairman of Uni-Bio Science, commented, “The primary half of 2026 introduced a difficult working surroundings, which we view as a transitional interval towards a extra diversified and all-round vary of product choices and promotional channels. Throughout the interval, we made important progress in strengthening each the breadth and depth of our industrial platform whereas advancing a strong pipeline of revolutionary therapies. Our omni-channel technique, spanning public hospitals, an increasing distributor community, retail pharmacy places, and main e-commerce platforms, continues to broaden affected person entry throughout China, together with deeper penetration into Tier-3 and Tier-4 cities. On the identical time, we’re executing a disciplined, product-specific commercialization strategy, tailoring our methods to the distinct market dynamics of every of our eight core merchandise. Past our home base, we’re accelerating our world ambitions. We’re advancing Bogutai®’s worldwide enlargement, along with our ongoing U.S. FDA submission, an necessary step towards establishing our first abroad commercialized remedy.
Our pipeline continues to advance meaningfully, from our proprietary EGF/FGF compound gel for wound care to next-generation BFS-based GeneSoft® formulations and our BMP-2 regenerative remedy, all underpinned by our proprietary ECO-KSFA® artificial biology and Organic Hydrogel know-how platforms. These innovation engines place us to proceed delivering differentiated, high-value therapies throughout prescribed drugs, medical gadgets, and medical aesthetics. We stay assured that our built-in technique, combining industrial excellence, world enlargement, and platform-driven innovation, will create sustainable long-term worth for our sufferers, companions, and shareholders.”
Hashtag: #Uni-BioScienceGroup
The issuer is solely liable for the content material of this announcement.
About Uni-Bio Science Group Restricted
Uni-Bio Science Group Restricted is an revolutionary biopharmaceutical enterprise listed on the Fundamental Board of The Inventory Alternate of Hong Kong Restricted in 2001 (Inventory Code: 00690.HK). The Group is dedicated to powering the development of regenerative drugs with next-generation artificial biology and sophisticated peptide innovation. Specializing in 4 core analysis areas—muscular-skeletal regeneration, pores and skin regeneration, ocular regeneration, and ENT regeneration—the Group has constructed a diversified product pipeline encompassing revolutionary biologics, high-value generic medication, and medical aesthetics. The Group operates GMP-compliant manufacturing bases in Beijing, Dongguan, and Shenzhen, with absolutely built-in capabilities spanning R&D, manufacturing, and industrial gross sales. Uni-Bio Science Group is devoted to be the worldwide chief in regenerative drugs, redefining how science restores and extends human life.
For additional info, please contact: ir@uni-bioscience.com
